Phoenix Bio

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

HBV with precore and basal core promoter mutations exhibits a high replication phenotype and causes ER stress-mediated cell death in humanized liver chimeric mice

2023/04/13

Uchida, T. Imamura, M. Hayes, C. N. Suehiro, Y. Teraoka, Y. Ohya, K. Aikata, H. Abe-Chayama, H. Ishida, Y. Tateno, C. Hara, Y. Hino, K. Okamoto, T. Matsuura, Y. Aizaki, H. Wake, K. Kohara, M. Liang, T. J. Oka, S. Chayama, K.
Hepatology. 2023 Mar 13. doi: 10.1097/HEP.0000000000000335.

Identification of SARS-CoV-2 M(pro) inhibitors containing P1′ 4-fluorobenzothiazole moiety highly active against SARS-CoV-2

2023/04/13

Higashi-Kuwata, N. Tsuji, K. Hayashi, H. Bulut, H. Kiso, M. Imai, M. Ogata-Aoki, H. .Ishii, T. Kobayakawa, T. Nakano, K. Takamune, N. Kishimoto, N. Hattori, S. I. Das, D. Uemura, Y. Shimizu, Y. Aoki, M. Hasegawa, K. Suzuki, S. Nishiyama, A. Saruwatari, J. Shimizu, Y. Sukenaga, Y. Takamatsu, Y. Tsuchiya, K. Maeda, K. Yoshimura, K. Iida, S. Ozono, S. Suzuki, T. Okamura, T. Misumi, S. Kawaoka, Y. Tamamura, H. Mitsuya, H.
Nat Commun. 2023 Feb 25;14(1):1076. doi: 10.1038/s41467-023-36729-0.

Establishment of hyperoxic cell culture system for predicting drug-induced liver injury: reducing accumulated lipids in hepatocytes derived from chimeric mice with humanized liver

2023/04/13

Ohtsuki, Y. Sanoh, S. Yamao, M. Kojima, Y. Kotake, Y. Tateno, C.
J Toxicol Sci. 2023;48(2):99-108. doi: 10.2131/jts.48.99.

Patient-derived monoclonal antibody neutralizes HCV infection in vitro and vivo without generating escape mutants

2023/04/13

Yokokawa, H. Shinohara, M. Teraoka, Y. Imamura, M. Nakamura, N. Watanabe, N. Date, T. Aizaki, H. Iwamura, T. Narumi, H. Chayama, K. Wakita, T.
PLoS One. 2022 Sep 22;17(9):e0274283. doi: 10.1371/journal.pone.0274283. eCollection 2022.

Prediction of the human pharmacokinetics of epyrifenacil and its major metabolite, S-3100-CA, by a physiologically based pharmacokinetic modeling using chimeric mice with humanized liver

2023/04/13

Hirasawa, K. Abe, J. Nagahori, H. Kitamoto, S.
Toxicol Appl Pharmacol. 2022 Mar 15;439:115912. doi: 10.1016/j.taap.2022.115912.

Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases

2023/04/13

Yarnall, M. T. N. Ioannidi, E. I. Schmitt-Ulms, C. Krajeski, R. N. Lim, J. Villiger, L. Zhou, W. Jiang, K. Garushyants, S. K. Roberts, N. Zhang, L. Vakulskas, C. A. Walker, J. A., 2nd. Kadina, A. P. Zepeda, A. E. Holden, K. Ma, H. Xie, J. Gao, G. Foquet, L. Bial, G. Donnelly, S. K. Miyata, Y. Radiloff, D. R. Henderson, J. M. Ujita, A. Abudayyeh, O. O. Gootenberg, J. S.
Nat Biotechnol. 2022 Nov 24. doi: 10.1038/s41587-022-01527-4.

Discovery of a first-in-class orally available HBV cccDNA inhibitor

2023/02/21

Wang, L. Zhu, Q. Zhang, J. D. Zhang, Y. Ni, X. Xiang, K. Jiang, J. Li, B. Yu, Y. Hu, H. Zhang, M. Wu, W. Zeng, J. Yan, Z. Dai, J. Sun, K. Zhang, X. Chen, D. Feng, S. Sach Peltason, L. Young, J. A. T. Gao, L.
J Hepatol. 2022 Dec 29:S0168-8278(22)03466-3. doi: 10.1016/j.jhep.2022.12.014.

Consideration of Commercially Available Hepatocytes as Cell Sources for Liver-Microphysiological Systems by Comparing Liver Characteristics

Horiuchi, S. Kuroda, Y. Komizu, Y. Ishida, S.
Pharmaceutics. 2022 Dec 24;15(1):55. doi: 10.3390/pharmaceutics15010055.

Long-term cell fate and functional maintenance of human hepatocyte through stepwise culture configuration

Sugahara, G. Ishida, Y. Lee, J. J. Li, M. Tanaka, Y. Eoh, H. Higuchi, Y. Saito, T.
FASEB J. 2023 Feb;37(2):e22750. doi: 10.1096/fj.202201292RR.

A novel cDNA-uPA/SCID/Rag2(-/-) /Jak3(-/-) mouse model for hepatitis virus infection and reconstruction of human immune system

2023/02/21

Uchida, T. Yuji, T. Imamura, M. Abe-Chayama, H. Makokha, G. N. Hayes, C. N. Aikata, H. Hamamura, S. Ishida, Y. Tateno, C. Shirouzu, T. Kawai, S. Tanaka, Y. Ohdan, H. Okada, S. Chayama, K.
J Viral Hepat. 2022 Dec 27. doi: 10.1111/jvh.13793. https://www.ncbi.nlm.nih.gov/pubmed/36575861

Characterization and Prevention of Hypovitaminosis C in Chimeric Mice with Humanized Livers

2023/02/21

Touchette, Erin K. Bates, Maria C. Johnson, Mitch C. O’Brien, Tracy C. Melton, Roger J. Long, Kelly R. Kakuni, Masakazu, Baginski, Matthew, Radiloff, Daniel R. Sagartz, John E.
Comparative Medicine 2022, 72(6): 355-363.

Pegylated interferon therapy-related microRNA-6126 downregulates sodium taurocholate cotransporting polypeptide expression in hepatocytes

2023/02/21

Fujita, K. Nishitsuji, H. Iwama, H. Tadokoro, T. Morishita, A. Mimura, S. Ono, M. Himoto, T. Shimotohno, K. Masaki, T.
Gene. 2022 Nov 24;853:147068. doi: 10.1016/j.gene.2022.147068.

Characterization of a KDM5 small molecule inhibitor with antiviral activity against hepatitis B virus

2023/02/21

Gilmore, S. A. Tam, D. Cheung, T. L. Snyder, C. Farand, J. Dick, R.Matles, M. Feng, J. Y.Ramirez, R.Li, L. Yu, H. Xu, Y.Barnes, D. Czerwieniec, G. Brendza, K. M. Appleby, T. C. Birkus, G. Willkom, M. Kobayashi, T. Paoli, E. Labelle, M. Boesen, T.Tay, C. H. Delaney, W. E. thNotte, G. T. Schmitz, U. Feierbach, B.
PLoS One. 2022 Dec 7;17(12):e0271145. doi: 10.1371/journal.pone.0271145. eCollection 2022.

Ivermectin Inhibits HBV Entry into the Nucleus by Suppressing KPNA2

2023/02/21

Nakanishi, A. Okumura, H. Hashita, T. Yamashita, A. Nishimura, Y. Watanabe, C. Kamimura, S. Hayashi, S. Murakami, S. Ito, K. Iwao, T. Ikeda, A. Hirose, T. Sunazuka, T. Tanaka, Y. Matsunaga, T.
Viruses. 2022 Nov 8;14(11):2468. doi: 10.3390/v14112468.

Physiologically based pharmacokinetic modeling for quantitative prediction of exposure to a human disproportionate metabolite of the selective Na(v)1.7 inhibitor DS-1971a, a mixed substrate of cytochrome P450 and aldehyde oxidase, using chimeric mice with humanized liver

2023/02/21

Asano, D. Nakamura, K. Nishiya, Y. Shiozawa, H. Takakusa, H. Shibayama, T. Inoue, S. I. Shinozuka, T. Hamada, T. Yahara, C. Watanabe, N. Yoshinari, K.
Drug Metab Dispos. 2023 Jan;51(1):67-80. doi: 10.1124/dmd.122.001000. Epub 2022 Oct 23.

コラーゲンビトリゲルを用いた新規肝細胞培養系における薬物動態研究

2022/12/01

渡 隆爾
関東化学発行誌

Designing receptor agonists with enhanced pharmacokinetics by grafting macrocyclic peptides into fragment crystallizable regions

2022/12/01

Sakai, K. Sugano-Nakamura, N. Mihara, E. Rojas-Chaverra, N. M. Watanabe, S. Sato, H. Imamura, R. Voon, D. C. Sakai, I. Yamasaki, C. Tateno, C. Shibata, M. Suga, H. Takagi, J. Matsumoto, K.
Nat Biomed Eng. 2022 Nov 7. doi: 10.1038/s41551-022-00955-6.

Evaluation of the mode of action and human relevance of liver tumors in male mice treated with epyrifenacil

2022/12/01

Fukunaga, S. Ogata, K. Eguchi, A. Matsunaga, K. Sakurai, K. Abe, J. Cohen, S. M. Asano, H.
Regul Toxicol Pharmacol. 2022 Oct 6;136:105268. doi: 10.1016/j.yrtph.2022.105268.

Fungal Secondary Metabolite Exophillic Acid Selectively Inhibits the Entry of Hepatitis B and D Viruses

2022/12/01

Kobayashi, C. Watanabe, Y. Oshima, M. Hirose, T. Yamasaki, M. Iwamoto, M. Iwatsuki, M. Asami, Y. Kuramochi, K. Wakae, K. Aizaki, H. Muramatsu, M. Sureau, C. Sunazuka, T. Watashi, K.
Viruses. 2022 Apr 6;14(4). pii: v14040764. doi: 10.339/v14040764.

Involvement of SLC16A1/MCT1 and SLC16A3/MCT4 in l-lactate transport in the hepatocellular carcinoma cell line

Mukai, Y. Yamaguchi, A. Sakuma, T. Nadai, T. Furugen, A. Narumi, K. Kobayashi, M.
Biopharm Drug Dispos. 2022 Oct;43(5):183-191. doi: 10.1002/bdd.2329. Epub 2022 Sep 22.